Stocktoria
COLLEGIUM PHARMACEUTICAL, INC COLL
COLLEGIUM PHARMACEUTICAL, INC (COLL) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $780.6M at a 8.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.34 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.152 |
| Retained earnings / assets | -0.061 |
| EBIT / assets | 0.108 |
| Equity / liabilities | 0.223 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| COLL | COLLEGIUM PHARMACEUTICAL, INC | 6/9 | 1.76 | 18.9 | +23.6% |
| CORT | CORCEPT THERAPEUTICS INC | 4/9 | 8.97 | 94.1 | +12.8% |
| EBS | Emergent BioSolutions Inc. | 6/9 | 3.44 | 8.4 | -28.8% |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | 4/9 | 0.82 | — | — |
| PCRX | Pacira BioSciences, Inc. | 8/9 | 3.08 | 141.1 | +3.6% |
| AMPH | Amphastar Pharmaceuticals, Inc. | 6/9 | 4.82 | 9.8 | -1.7% |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | 3/9 | 5.11 | — | +8.6% |
About COLLEGIUM PHARMACEUTICAL, INC
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
FAQ
Is COLL financially healthy?
COLLEGIUM PHARMACEUTICAL, INC's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does COLL pay a dividend?
No, COLLEGIUM PHARMACEUTICAL, INC does not currently pay a dividend.
How profitable is COLL?
In FY2025, COLLEGIUM PHARMACEUTICAL, INC had a net margin of 8.1% and a return on equity of 20.8%.
Is COLL overvalued or undervalued?
COLLEGIUM PHARMACEUTICAL, INC trades at about 14.9× trailing earnings — below its 10-year norm (10-year range 9.6×–31.8×, median 25.6×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for COLL?
The average Wall-Street price target for COLLEGIUM PHARMACEUTICAL, INC is $54.33, about 111.4% above the recent price, from 6 analysts.
Is COLL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on COLLEGIUM PHARMACEUTICAL, INC: a Piotroski F-score of 6/9, an Altman Z″ in the grey zone, a P/E of about 18.9×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.